How to Buy Cronos Group Stock
Cronos Group Inc
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States.
Cronos Group stock last closed at $1.93, down 3.02% from the previous day, and has decreased 21.54% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.14 percentage points. Cronos Group stock is currently +20.63% from its 52-week low of $1.60, and -24.02% from its 52-week high of $2.54.
As of Jun 13, 2025, there are 385.42M shares of CRON outstanding. The market cap of CRON is $743.86M. In the last 24 hours, 1.16M CRON shares were traded.
How to Buy Cronos Group Stock
Wondering how to invest in Cronos Group stock? Here's how.
- Choose where to buy Cronos Group stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Cronos Group stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Fund your investment account: Select your payment method and add your information.
- Analyze Cronos Group stock: The Cronos Group ticker symbol is CRON. Is Cronos Group stock a good investment? Should you buy shares of CRON? How do CRON's underlying business fundamentals look? Do top analysts think Cronos Group is a good buy? Why has CRON's stock price moved recently? (Hint: Our stock research tools can help you figure out if CRON is a good stock to buy).
- Place your CRON trade: Decide if you will purchase CRON shares at the current market price or use a limit order to purchase CRON stock at a specific price.
- Keep an eye on your investment in CRON: Create a watchlist to important notifications about your position in Cronos Group stock.
Step 1: Choose where to buy Cronos Group stock
You need a brokerage account to access the NASDAQ market and buy CRON shares.
Our recommended brokerage: eToro
In our opinion, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal information so you are able to invest in CRON stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create a new brokerage account.
- Submit your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've opened your account on the best stock app for beginners, you can securely and quickly fund your account:
Watch this video walkthrough if you need help depositing funds into your investment account.
Step 4: Analyze Cronos Group stock
After you have decided on the best place to buy Cronos Group stock, it's absolutely critical to evaluate their stock prior to buying, so you can wrap your head around the risk as well as the opportunity.
Cronos Group Metrics
CRON Due Diligence Score
WallStreetZen was designed to help everyday investors do better fundamental analysis in less time.
You can see all of the due diligence checks on CRON's stock page.
How is CRON stock valued?
You can use many financial metrics, analyses, models, and charts to gauge CRON's true value.
Using relative valuations ratios:
- CRON may be undervalued based on its P/E ratio of 13.79x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of -23.1x
- CRON could be undervalued based on its P/B ratio of 0.7x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 2.26x
You can access additional valuation analysis on CRON's stock here.
CRON Financials at a glance
Positive Health Checks:
- Total CRON debt is lower than 5 years ago, relative to shareholder equity.
- CRON has a low debt to equity ratio of 0.04.
- There are more short-term assets than short-term liabilities on the CRON balance sheet.
- CRON profit margin has gone up from -61.3% to 39.7% in the past year.
- There are more short-term assets than long-term liabilities on the CRON balance sheet.
- CRON has $838.56M in cash and short term investments. This is sufficient to cover its annual cash burn of $6.99M.
- CRON has cash burn of 6994000. It has sufficient cash and short-term investments to cover this for at least one year.
You can dig deeper into what analysts are forecasting on the Cronos Group stock forecast page.
CRON Momentum
How is CRON performing as a company?
Last year, CRON earnings were $49.44M. During the last 5 year, CRON's earnings have grown by -44.29% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 6.39%.
Last year, CRON revenue was $124.59M. Over the last five year, CRON's revenue has gone up by 33.69% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 9.6%.
You can analyze CRON's earnings and revenue performance here.
Latest Insiders Trades at CRON
In the last year, executives and large shareholders at CRON have sold more shares than they have bought.
Terrence Gregory Joseph Doucet, General Counsel and Corporate Secretary of CRON, was the latest CRON insider to sell. They sold $24,186.76 worth of CRON stock on May 12, 2025.
Research more about who owns CRON stock here.
Does CRON provide a stable income stream?
No, Cronos Group doesn't provide an income stream by paying out dividends.
CRON Social Trading Data
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your CRON trade
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at an exact price limit, place a limit order.
Click the Open Trade button and your broker will place your order.
If you require additional assistance investing in stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your investment in CRON
Now that you own some CRON stock, you'll want to stay up-to-date on your new stock purchase.
Put CRON on a watchlist to keep track of your CRON stock.
CRON Feed
How to Buy Stock in Cronos Group
To summarize, here are the 6 steps to buy stock in Cronos Group:
- Choose where to buy Cronos Group stock
- Sign up for a brokerage account
- Fund your investment account
- Analyze Cronos Group stock
- Place your CRON trade
- Keep an eye on your investment in CRON
If you need a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to monitor your investment in Cronos Group, create a watchlist on WallStreetZen today.
Other "How To" Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.